Mortality burden related to infection with carbapenem-resistant Gram-negative bacteria among haematological cancer patients: A retrospective cohort study

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 11, 2015, Pages 3146-3153

  Andria, Nizar ^a   Henig, Oryan ^b   Kotler, Offer ^c   Domchenko, Alexander ^c   Oren, Ilana ^c,d   Zuckerman, Tsila ^c,e   Ofran, Yishai ^c,e   Fraser, Drora ^f   Paul, Mical ^c,d  

^a Medicine B   (Israel)

^b CARMEL MEDICAL CENTER   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^d Division of Infectious Diseases   (Israel)

^e NONE   (Israel)

^f BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CARBAPENEM; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE;

ACUTE LEUKEMIA; ADULT; ANTIBIOTIC THERAPY; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; COHORT ANALYSIS; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE SEPSIS; HEMATOLOGIC MALIGNANCY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPHIL COUNT; PROGNOSIS; PROPENSITY SCORE; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; AGED; ANTIBIOTIC RESISTANCE; BACTEREMIA; COMPLICATION; DRUG EFFECTS; GRAM NEGATIVE INFECTION; HEMATOLOGIC DISEASE; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; SURVIVAL ANALYSIS;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAM RESISTANCE; CARBAPENEMS; COHORT STUDIES; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84949008433     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv218     Document Type: Article

References (34)

1. Dautzenberg MJ, Ossewaarde JM, de Kraker ME et al. Successful control of a hospital-wide outbreak of OXA-48 producing Enterobacteriaceae in the Netherlands, 2009 to 2011. Euro Surveill 2014; 19: pii=20723.
2. Enfield KB, Huq NN, Gosseling MF et al. Control of simultaneous outbreaks of carbapenemase-producing Enterobacteriaceae and extensively drug-resistant Acinetobacter baumannii infection in an intensive care unit using interventions promoted in the Centers for Disease Control and Prevention 2012 Carbapenemase-resistant Enterobacteriaceae Toolkit. Infect Control Hosp Epidemiol 2014; 35: 810-7.
3. Schwaber MJ, Lev B, Israeli A et al. Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin Infect Dis 2011; 52: 848-55.
4. Canton R, Akova M, Carmeli Y et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect 2012; 18: 413-31.
5. Khan AU, Nordmann P. Spread of carbapenemase NDM-1 producers: the situation in India and what may be proposed. Scand J Infect Dis 2012; 44: 531-5.
6. Zuckerman T, Benyamini N, Sprecher H et al. SCT in patients with carbapenem resistant Klebsiella pneumoniae: a single center experience with oral gentamicin for the eradication of carrier state. Bone Marrow Transplant 2011; 46: 1226-30.
7. Paul M, Bishara J, Levcovich A et al. Effectiveness and safety of colistin: prospective comparative cohort study. J Antimicrob Chemother 2010; 65: 1019-27.
8. Leibovici L, Vidal L, Paul M. Aminoglycoside drugs in clinical practice: an evidence-based approach. J Antimicrob Chemother 2009; 63: 246-51.
9. Garcia-Sureda L, Domenech-Sanchez A, Barbier M et al. OmpK26, a novel porin associated with carbapenem resistance in Klebsiella pneumoniae. Antimicrob Agents Chemother 2011; 55: 4742-7.
10. Lavigne JP, Cuzon G, Combescure C et al. Virulence of Klebsiella pneumoniae isolates harboring blaKPC-2 carbapenemase gene in a Caenorhabditis elegans model. PLoS One 2013; 8: e67847.
11. Siu LK, Lin JC, Gomez E et al. Virulence and plasmid transferability of KPC Klebsiella pneumoniae at the Veterans Affairs Healthcare System of New Jersey. Microb Drug Resist 2012; 18: 380-4.
12. Bhargava A, Hayakawa K, Silverman E et al. Risk factors for colonization due to carbapenem-resistant Enterobacteriaceae among patients exposed to long-term acute care and acute care facilities. Infect Control Hosp Epidemiol 2014; 35: 398-405.
13. Marchaim D, Chopra T, Bhargava A et al. Recent exposure to antimicrobials and carbapenem-resistant Enterobacteriaceae: the role of antimicrobial stewardship. Infect Control Hosp Epidemiol 2012; 33: 817-30.
14. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S et al. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 2008; 52: 1028-33.
15. Abad C, Fearday A, Safdar N. Adverse effects of isolation in hospitalised patients: a systematic review. J Hosp Infect 2010; 76: 97-102.
16. Falagas ME, Tansarli GS, Karageorgopoulos DE et al. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis 2014; 20: 1170-5.
17. Sorror ML, Maris MB, Storb R et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912-9.
18. Falagas ME, Lourida P, Poulikakos P et al. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother 2014; 58: 654-63.
19. Bodey GP. Evolution of antibiotic therapy for infection in neutropenic patients: studies at M. D. Anderson Hospital. Rev Infect Dis 1989; 11 Suppl 7: S1582-90.
20. Bodey GP, Middleman E, Umsawadi T et al. Infections in cancer patients. Results with gentamicin sulfate therapy. Cancer 1972; 29: 1697-701.
21. Yahav D, Farbman L, Leibovici L et al. Colistin: new lessons on an old antibiotic. Clin Microbiol Infect 2012; 18: 18-29.
22. Yahav D, Lador A, Paul M et al. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 2011; 66: 1963-71.
23. Aydemir H, Celebi G, Piskin N et al. Mortality attributable to carbapenem-resistant nosocomial Acinetobacter baumannii infections in a Turkish university hospital. Jpn J Infect Dis 2012; 65: 66-71.
24. Ben-David D, Kordevani R, Keller N et al. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infect 2012; 18: 54-60.
25. Borer A, Saidel-Odes L, Riesenberg K et al. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infect Control Hosp Epidemiol 2009; 30: 972-6.
26. Chang HJ, Hsu PC, Yang CC et al. Risk factors and outcomes of carbapenem-nonsusceptible Escherichia coli bacteremia: a matched case-control study. J Microbiol Immunol Infect 2011; 44: 125-30.
27. de Gouvea EF, Martins IS, HalpernM et al. The influence of carbapenem resistance on mortality in solid organ transplant recipients with Acinetobacter baumannii infection. BMC Infect Dis 2012; 12: 351.
28. Esterly JS, Griffith M, Qi C et al. Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections. Antimicrob Agents Chemother 2011; 55: 4844-9.
29. Hussein K, Raz-Pasteur A, Finkelstein R et al. Impact of carbapenem resistance on the outcome of patients' hospital-acquired bacteraemia caused by Klebsiella pneumoniae. J Hosp Infect 2013; 83: 307-13.
30. Mouloudi E, Protonotariou E, Zagorianou A et al. Bloodstreaminfections caused by metallo-ß-lactamase/Klebsiella pneumoniae carbapenemaseproducing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes. Infect Control Hosp Epidemiol 2010; 31: 1250-6.
31. Pena C, Suarez C, Gozalo M et al. Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections. Antimicrob Agents Chemother 2012; 56: 1265-72.
32. Routsi C, Pratikaki M, Platsouka E et al. Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes. Infection 2010; 38: 173-80.
33. Shorr AF, Zilberberg MD, Micek ST et al. Predictors of hospital mortality among septic ICU patients with Acinetobacter spp. bacteremia: a cohort study. BMC Infect Dis 2014; 14: 572.
34. Suarez C, Pena C, Gavalda L et al. Influence of carbapenem resistance on mortality and the dynamics of mortality in Pseudomonas aeruginosa bloodstream infection. Int J Infect Dis 2010; 14 Suppl 3: e73-8.